


Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-Dec-2022
 Document Type: USP Monographs
 DocId: GUID-DA26EC4D-5CA8-4A20-BF76-F3FA31269F18_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M19920_02_01
 DOI Ref: k3sch

© 2025 USPC
 Do not distribute

Colistin Sulfate



Colistin, sulfate;
 Colistins sulfate

CAS RN[®]: 1264-72-8; UNII: WP15DXU577.

DEFINITION

Colistin Sulfate is the sulfate salt of an antibacterial substance produced by the growth of *Bacillus polymyxa* var. *colistinus*. It has a potency equivalent to NLT 500 µg of colistin/mg.

IDENTIFICATION

Delete the following:

▲ A. PROCEDURE ▲ (USP 1-Dec-2022)

Add the following:

▲ A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy](#): 197A or 197K ▲ (USP 1-Dec-2022)

• B. [IDENTIFICATION TESTS—GENERAL \(191\)](#), [Chemical Identification Tests, Sulfate](#): Meets the requirements

Delete the following:

▲ C. LIQUID CHROMATOGRAPHIC IDENTIFICATION TEST ▲ (USP 1-Dec-2022)

Add the following:

▲ C. The retention times of the colistin A and colistin B peaks of the *Sample solution* correspond to those of the *Standard solution*, as obtained in the test for *Composition*. ▲ (USP 1-Dec-2022)

ASSAY

Change to read:

• PROCEDURE

Analysis: Proceed as directed for *Colistin* in [Antibiotics—Microbial Assays \(81\)](#).

Acceptance criteria: NLT 500 µg ▲ of colistin ▲ (USP 1-Dec-2022) /mg

Add the following:

▲ IMPURITIES

• ORGANIC IMPURITIES

Solution A: 4.5 g of [anhydrous sodium sulfate](#) in 900 mL of [water](#), adjusted with [diluted phosphoric acid](#) to a pH of 2.4 and diluted with [water](#) to 1000 mL

Mobile phase: *Solution A* and [acetonitrile](#) (78:22)

Diluent: [Water](#) and [acetonitrile](#) (80:20)

Sensitivity solution: 5 µg/mL of [USP Colistin Sulfate RS](#) in *Diluent*

Standard solution: 0.5 mg/mL of [USP Colistin Sulfate RS](#) in *Diluent*

Sample solution: 0.5 mg/mL of Colistin Sulfate in *Diluent*

Chromatographic system

(See [Chromatography \(621\), System Suitability.](#))

Mode: LC

Detector: UV 215 nm

Column: 4.6-mm × 25-cm; 3-µm packing L1

Column temperature: 50°

Flow rate: 1.0 mL/min

Injection volume: 20 µL

System suitability

Samples: *Sensitivity solution* and *Standard solution*

[NOTE—See [Table 1](#) for the relative retention times. Use the reference chromatogram provided with the lot of [USP Colistin Sulfate RS](#) to identify the peaks.]

Suitability requirements

Peak-to-valley ratio: NLT 1.1 for the ratio of the height of the peak that immediately follows the colistin B peak to the height of the valley between the two peaks, *Standard solution*

Resolution: NLT 2.0 between polymyxin E6 and 7-L-isoleucinepolymyxin E2; NLT 3.0 between 2,3-dehydro colistin A and colistin A, *Standard solution*

Signal-to-noise ratio: NLT 10 for the colistin A peak, *Sensitivity solution*

Analysis

Sample: *Sample solution*

Calculate the percentage of each individual impurity (for peaks other than colistin A; colistin B; polymyxins E3, E4, E6, E7; 7-L-valinepolymyxin E2; 7-L-isoleucinepolymyxin E2; 7-L-norvalinepolymyxin E1; colistin III; and 2,3-dehydro colistin A) in the portion of Colistin Sulfate taken:

$$\text{Result} = (r_U/r_T) \times (1/F) \times 100$$

r_U = peak response of each individual impurity

r_T = sum of all the peak responses

F = relative response factor

Acceptance criteria: See [Table 1](#). The reporting threshold is 0.35%.

Table 1

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria (%)
7-L-Valinepolymyxin E2 ^a and polymyxin E4 ^b	0.28	1.0	—
Polymyxin E6 ^c	0.39	1.0	NMT 4.5
7-L-Isoleucinepolymyxin E2 ^d	0.42	1.0	NMT 2.5
Colistin B ^e	0.50	1.0	—

Name	Relative Retention Time	Relative Response Factor	Acceptance Criteria (%)
Polymyxin E3 ^f	0.56	1.0	NMT 5.5
7-L-Norvalinepolymyxin E1 ^g	0.59	1.0	NMT 4.5
Colistin III ^h	0.82	1.0	NMT 8.5
2,3-Dehydro colistin A ⁱ	0.90	3.3	NMT 1.5
Colistin A ^j	1.00	1.0	—
Polymyxin E7 ^k	1.1	1.0	NMT 5.0
Sum of 7-L-valinepolymyxin E2 and polymyxin E4	—	—	NMT 3.0
Sum of colistin A, colistin B, polymyxin E3, polymyxin E4, polymyxin E6, polymyxin E7, 7-L-valinepolymyxin E2, 7-L-isoleucinepolymyxin E2, 7-L-norvalinepolymyxin E1, colistin III, and 2,3-dehydro colistin A	—	—	NLT 86.0
[N ⁴ -Dab ⁵] Colistin A ^l	1.3	1.0	NMT 4.0
Any individual impurity other than [N ⁴ -Dab ⁵] Colistin A	—	1.0	NMT 2.5; the total number of impurities exceeding 1.0 is NMT 4
Total impurities	—	—	NMT 11.0▲ (USP 1-Dec-2022)

^a N²-(6-Methyl-1-oxoheptyl)-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-valyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.

^b N²-(1-Oxoheptyl)-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-leucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.

^c N²-[(6S)-3-Hydroxyl-6-methyl-1-oxooctyl]-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-leucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.

^d N²-(6-Methyl-1-oxoheptyl)-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-isoleucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.

^e N²-(6-Methyl-1-oxoheptyl)-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-leucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.

^f N²-(1-Oxooctyl)-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-leucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.

^g N²-[(S)-6-Methyl-1-oxooctyl]-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-norvalyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.

^h N²-[(S)-6-Methyl-1-oxooctyl]-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-isoleucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.

ⁱ N²-[(S,E)-6-Methyloct-2-enoyl]-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-leucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.

- j N²-[(S)-6-Methyl-1-oxooctyl]-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-leucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.
- k N²-(7-Methyl-1-oxooctyl)-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-D-leucyl-L-leucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.
- l N²-[(S)-6-Methyl-1-oxooctyl]-L-2,4-diaminobutanoyl-L-threonyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-4-[(S)-2-aminobutanoyl]-D-leucyl-L-leucyl-L-2,4-diaminobutanoyl-L-2,4-diaminobutanoyl-L-threonine, cyclic (10→4)-peptide.

SPECIFIC TESTS

- [pH \(791\)](#): 4.0–7.0, in 10 mg/mL solution
- [Loss on Drying \(731\)](#).

Sample: 100 mg

Analysis: Dry in a capillary-stoppered bottle under vacuum at a pressure NMT 5 mm of mercury at 60° for 3 h.

Sample: It loses NMT 7.0% of its weight.

Add the following:

▲ • COMPOSITION

Solution A, Mobile phase, Diluent, Sensitivity solution, Standard solution, Sample solution, Chromatographic system, and System suitability: Proceed as directed in the test for *Organic Impurities*.

Analysis

Sample: *Sample solution*

Calculate the percentage of each individual component (colistin A; colistin B; polymyxins E3, E4, E6, E7; 7-L-valinepolymyxin E2; 7-L-isoleucinepolymyxin E2; 7-L-norvalinepolymyxin E1; colistin III; and 2,3-dehydro colistin A) in the portion of Colistin Sulfate taken:

Result = $(r_U/r_T) \times (1/F) \times 100$

r_U = peak response of each individual component

r_T = sum of all the peak responses

F = relative response factor

Acceptance criteria: See [Table 1](#). ▲ (USP 1-Dec-2022)

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight containers.
- **USP REFERENCE STANDARDS (11).**
[USP Colistin Sulfate RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
COLISTIN SULFATE	Julie Zhang Associate Science & Standards Liaison	BIO42020 Biologics Monographs 4 - Antibiotics

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. 47(4)

Current DocID: GUID-DA26EC4D-5CA8-4A20-BF76-F3FA31269F18_2_en-US

DOI: https://doi.org/10.31003/USPNF_M19920_02_01

DOI ref: [k3sch](#)